Navigation Links
Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
Date:10/21/2009

ond to tumor cells by blocking PS-mediated immunosuppression. Bavituximab is being tested in combination with chemotherapy in Phase II trials in advanced lung cancer and advanced breast cancer. Interim results in these trials have been encouraging, with objective tumor response rates that compare favorably to chemotherapy alone.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(®). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that that the rate of objective tumor response for future trials will not be consistent with the objective tumor response experienced in the Phase II trials and the risk that the standard docetaxel response rate will not be improved as a result of the combination therapy. Factors that could cause actual results to differ materially or otherwise adversely impact the company's a
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
2. Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
3. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
5. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
6. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
7. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
8. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
9. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... Company (Nasdaq: PRGO;TASE) today announced that its Board ... per share, payable on March 20, 2012 to ... Perrigo Company is a leading global healthcare ... generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, ...
... Corporation (NASDAQ: LIFE ) today announced ... Leader, GE Molecular Diagnostics, has joined the company as ... of experience in the diagnostics industry, including leadership positions ... As President, Medical Sciences at Life Technologies, ...
Cached Medicine Technology:Ronnie Andrews Joins Life Technologies as President, Medical Sciences 2Ronnie Andrews Joins Life Technologies as President, Medical Sciences 3Ronnie Andrews Joins Life Technologies as President, Medical Sciences 4
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, LunaDress.co.uk has updated ... dresses and related accessories. Now, all of the models at LunaDress.co.uk ... moment a groom lifts the wedding veil can turn out to ... stunning charm. A wedding veil can always bring surprise to a ... suggestions on how to choose veils for a big day ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
(Date:12/25/2014)... 25, 2014 Residents at ... recently showed their generous spirit by providing holiday ... County Parenting Network- Grandparents Raising Grandchildren program. , ... around the largest Christmas tree on the campus ... by residents of the Abernethy Village Association (AVA). ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... ... an all-new chapter, Dating Games Men Play: 16 Men,s Deadly Dating Patterns that will help ... book also includes specific dating advice for single mothers, women over 45, successful professionals and ... (PRWEB) January 28, ...
... ... Sunquest Collection Manager™ automated specimen collection software , ... (PRWEB) January 28, 2010 -- ... announced that Valley Medical Center, in Renton, Washington, has licensed Sunquest ...
... Bella’s House Community ... in and around the Houston, TX area. We have added two new ways parents can ... ... Community News is dedicated to supporting parents with special needs children by acting as a ...
... identified several cytokines, cytokine-related factors, and chemokines that increase ... These findings confirm those of earlier studies which suggest ... and disease progression may be prevented. Complete findings of ... Arthritis & Rheumatism , a journal of the ...
... new study led by Mount Sinai researchers in collaboration ... for Disease Control and Prevention, has found higher prenatal ... be connected with disruptive and problem behaviors in children ... study, which is the first to examine the effects ...
... 30 Groups Emphasize The Urgency Of Repealing Medicare ... Americans , WASHINGTON , Jan. 27 ... professionals and providers recently sent a letter to Congressional ... process for Medicare Part B outpatient therapy services. Without ...
Cached Medicine News:Health News:New Paperback Dating Advice Book, Love in 90 Days, Reveals 16 Men's Dead-End Dating Patterns and What To Do About Them 2Health News:New Paperback Dating Advice Book, Love in 90 Days, Reveals 16 Men's Dead-End Dating Patterns and What To Do About Them 3Health News:Sunquest Information Systems Enters Into Business Relationship with Valley Medical Center of Washington 2Health News:Announcing the Launch of a New Workshop and Forum for Parents of Disabled Children 2Health News:Announcing the Launch of a New Workshop and Forum for Parents of Disabled Children 3Health News:Blood test can predict rheumatoid arthritis before symptoms arise 2Health News:Mount Sinai finds prenatal exposure to certain chemicals affects childhood neurodevelopment 2Health News:Congress Urged to Take Immediate Action to Ensure Frail Patients Continue to Receive Critical Therapy Services 2Health News:Congress Urged to Take Immediate Action to Ensure Frail Patients Continue to Receive Critical Therapy Services 3